Study the efficacy of intralesional pentoxifylline versus triamcinolone acetonide in keloid scars patients
Keywords:
Keloid, intralesional pentoxifylline, intralesional triamcinolone acetonideAbstract
Keloids are prevalent fibro-proliferative tumors, and treating them is still a challenge although intralesional injections of triamcinolone acetonide (TAC) are effective, they have frequently linked adverse effects. Pentoxifylline (PTX) is an anti-fibrotic and anti-inflammatory, and vasodilator. It has not yet been tested for intralesional injection in keloids. The aim of the study is to study the efficacy of intralesional pentoxifylline versus triamcinolone acetonide in keloid scars of 40 patients. In this study, 40 patients with keloid scars regardless of the cause of keloid born, 20 patients have injected with intralesional triamcinolone acetonide, and 20 patients with intralesional pentoxifylline every two weeks until the lesion flatted or a maximum 6 sessions. Evaluation of Patient response to treatment was done by utilizing the verbal rating scale and Vancouver scar scale. Between groups A& B there is no statistically significant difference in height, color, the surface of the keloid, pigmentation consistency, verbal rating scale, visual analog scale (improvement in keloid), patient satisfaction, and several sessions for best results.
Downloads
References
Aronoff SC, Quinn FJ, Carpenter LS, Novick WJ (1994) Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr 125: 992–997. https://link.springer.com/chapter/10.1007/978-3-0348-8960-5_5
Atiyeh, B.S., Costagliola, M. and Hayek, S.N. (2005) Keloid or Hypertrophic Scar The Controversy Review of the Literature. Annals of Plastic Surgery, 54, 676-680. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009623
Bayat A, McGrouther D A, Ferguson M W J. (2003) Skin scarring BMJ 326 :88.https://www.bmj.com/content/326/7380/88
Bayat A, McGrouther DA. (2005 )Clinical management of skin scarring. 4:165–73
Bertram G.Katzung, ,Anthony J.Trevor, (2015)13th edition ,united states,McGraw-Hill education,p318
Br J Dermatol (1990)Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, sleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin,123(3):339-346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228656
Breivik, E.K., Björnsson, G.A. and Skovlund, E. (2000) A Comparison of Pain Rating Scales by Sampling from Clinical Trial Data. Clinical Journal of Pain, 16, 22-28. https://www.scirp.org/reference/ReferencesPapers.aspx?ReferenceID=1216544
Butler PD, Longaker MT, Yang GP (2008) Current progress in keloid research and treatment. J Am Coll Surg. , 206(4):731–741
Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. (2002) Triamcinolone stimulates bFGF production and inhibits TGF-beta1 production by human dermal fibroblasts. Dermatol Surg ,28(8):704–709
Carswell L, Borger J. Hypertrophic Scarring Keloids. StatPearls.( 2021 )Salem A, Assaf M, Helmy A, et al. Role of vascular endothelial growth factor in keloids: a clinicopathologic study. Int J Dermatol. 9;48(10):1071–1077
Chanana, M. (2018). Empirical study: relationship between self efficacy and academic performance. International Journal of Health & Medical Sciences, 1(1), 28-34. https://doi.org/10.31295/ijhms.v1n1.36
Fischer M, Wohlrab J, Marsch W. Crux medicorum(2001)ulcerated radiation-induced fibrosis-successful therapy with pentoxifylline and vitamin E. Eur J Dermatol. ,11(1):38-40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228656
Hosseini F, Mohammadbeigi A, Aghaali M, et al.(2019) Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: a randomized trial. J Res Med Sci, 24:89.
Isaac C, Carvalho VF, Paggiaro AO, de Maio M, Ferreira MC.(2010) Intralesional pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic scars. Burns ,831-835https://europepmc.org/article/MED/20064692.
Kaya V, Yazkan R, Yıldırım M, et al. (2014)The relation of radiationinduced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study. Med Sci Monit. ,21(20):290-296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471854
Lee YI, Kim J, Yang CE, et al.(2019) Combined therapeutic strategies for keloid treatment. Dermatol Surg. ,45(6):802-810. https://sci-hub.se/10.1097/DSS.0000000000001695
Leventhal D, Furr M, Reiter D. (2006)Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. ,8(6):362–368
Limandjaja GC, Niessen FB, Scheper RJ, et al. (2020)The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol,8:360.
Liu J, Chen F, Wei Z, et al.(2018) Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis. Oral Dis. ,24(5):706-716. https://reference.medscape.com/medline/abstract/28737007
Mikhael NW, El-Esawy FM.(2015) Intralesional pentoxifylline in the treatment of lepromatous ulcers. J Egypt Womenʼs Dermatologic Soc ,12(2):102-107
Mustoe TA, Cooter RD, Gold MH, et al. (2002)International Advisory Panel on Scar Management International clinical recommendations on scar management,110(2):560–571
Robert Baran, MD,Howard I.Maibach,MD(2017)textbook of cosmetic dermatology, fifth edition,U.S.A , Taylor&francis group,p349 -357
Roques C, Tèot L.(2008) The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wound. ,7(3):137–145.
Smith JF, Shindel AW, Huang Y-C, et al.( 2011) Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. ,13(2):322-325. https://pubmed.ncbi.nlm.nih.gov/21102473
Srivastava S, Patil A, Prakash C, et al.(2018) Comparison of intralesional triamcinolone acetonide, 5-fluorouracil, and their combination in treatment of keloids. World J Plast Surg.,7(2):212-219. https://europepmc.org/abstract/MED/29098115
Sullivan T, Smith J, Kermode J, et al. (1990)Rating the burn scar. J Burn Care Rehabil ,11:256-26
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Tan A, Martinez Luna O, Glass DA 2nd. Pentoxifylline for the prevention of postsurgical keloid recurrence. Dermatol Surg.2020;46(10):1353-1356
Trisliana Perdanasari A, Lazzeri D, Su W, et al(2014) Recent developments in the use of intralesional injections keloid treatment,41(6):620–629 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063260
Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol. 2004 Summer;9(2):103-11
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
